Technology

Cancer Target Atlas Enabled by MabArrayTM:

  • Industrialized hybridoma development capability for efficient generation of large-scale library against cancer/immune proteomes

  •  Current library of 100,000 clones enables large-scale target discovery

  • Difficult protein classes can be discovered

  • Target Atlas for specific tumor/normal tissue type allows combinatorial targeting by ADC/CAR-T/Bi-specific molecules

  • Ready access to clinical samples/collaborators in China

  • Fast asset delivery time

Technology 1:  MabArrayTM Tissue sample screening for tumor-specific targets

Picture6.png

Technology 2:  MabArrayTM based Cancer Target discovery

Picture7.png